PepGen’s 64% Collapse Ignites Class Action Risk as Lead Drug Fails to Show Efficacy

The immediate trigger for PepGen's collapse is a stark clinical failure. On March 31, shares plunged approximately 64% to roughly $1.52 following the release of Phase 2 data for its lead drug, PGN-EDODM1. The core of the disaster is the efficacy readout from the 5 mg/kg dose cohort. The treatment arm achieved a mean splicing correction of just 7.3% versus 6.8% for placebo. This minuscule, statistically insignificant difference fails to establish any clinical benefit, directly shattering the investment thesis for the company's most advanced program.

This blow is compounded by a pre-existing regulatory overhang. In early March, the U.S. FDA placed a partial clinical hold on the FREEDOM2 trial, citing concerns with preclinical studies. While the hold allowed dosing to continue internationally, it created a persistent negative narrative and had already triggered a steep sell-off. The new data didn't just disappoint; it validated the market's worst fears about the drug's potential, turning a regulatory pause into a clinical dead end.

The investment question now is whether this is a fundamental break or a temporary mispricing. The data is binary and severe-no meaningful efficacy at the tested dose. Yet, the company points to a higher 10 mg/kg cohort, with data expected in the second half of 2026, as a potential lifeline. For now, the market is treating the 5 mg/kg failure as a decisive event, pricing out the near-term value of the lead asset.

The Legal Landscape: A Pattern of Scrutiny

The market's violent reaction to the clinical data is now converging with a formal legal probe. On March 19, just two weeks after the Phase 2 failure, Pomerantz LLP announced an investigation into potential securities fraud at PepGen. This is not a new development; it is the third such probe by the firm in the past 18 months. The pattern is clear: Pomerantz has been actively investigating the company since at least April 2025, with investigations announced in April, June, and now March 2026. This consistent scrutiny signals a persistent legal overhang that the market may have been slow to price in.

The current investigation specifically targets the company's disclosures around the partial clinical hold placed by the FDA in early March. The probe will likely examine whether management adequately warned investors about the risks tied to those preclinical studies before the hold was announced. The timing is critical. The stock had already fallen sharply on the hold news in March, but the subsequent release of the 5 mg/kg data has compounded the damage, creating a classic event-driven setup for legal action. When a company's stock price collapses on new negative information, it often triggers a wave of shareholder lawsuits alleging that earlier statements were misleading or omitted material facts.

The sheer magnitude of the decline underscores the potential for a class action. Over the past 120 days, PepGen's shares have fallen more than 65%. This extreme volatility, combined with the firm's established pattern of investigation, creates a fertile ground for legal claims. For investors, the Pomerantz probe is a tangible catalyst that could crystallize the company's regulatory and clinical setbacks into a financial liability. It adds another layer of risk to an already precarious situation, where the lead asset's failure has left the company with few near-term options.

The Setup: Valuation, Liquidity, and What's Next

The immediate risk/reward is stark. PepGen now trades with a market capitalization of roughly $120 million. This valuation is deeply negative, with a trailing P/E of -1.33 and an enterprise value of -28.9 million. The negative EV, which accounts for the company's cash and debt, signals that the market is pricing in a near-total wipeout of the lead asset's value. The stock's 64.6% drop over the past five days and a 68.6% decline over 20 days highlight extreme volatility, a key factor for any legal action.

A pattern of insider selling over the past six months adds to the pressure. While one entity, Science Enterprises, made a purchase, the company's executives have been net sellers. The President and CEO, CFO, and an EVP have all sold shares, with the CEO alone offloading 5,275 shares. This activity, occurring against a backdrop of a collapsing stock, raises questions about management's confidence and could be cited in any securities case.

The sole near-term catalyst is the data from the higher 10 mg/kg dose cohort, expected in the second half of 2026. This is the last remaining clinical hope for the lead drug. For now, the market is treating the 5 mg/kg failure as definitive, pricing out the value of this future readout. The setup is a binary event: the data either provides a lifeline or confirms the asset is dead.

The key legal risk is whether a class action can gain momentum. The probe by Pomerantz LLP targets disclosures around the FDA hold, but the stock's low float and extreme volatility complicate matters. A class action requires a group of investors who bought within a specific window and suffered losses. With shares trading at $1.73 and a turnover rate of just 0.58%, the liquidity is thin. This makes it harder to establish a clear trading pattern and could limit the pool of potential plaintiffs. Yet, the sheer magnitude of the decline-over 65% in the past 120 days-creates a strong factual basis for alleging material misrepresentation or omission. The legal overhang is real, but its practical impact hinges on the stock's ability to find a stable trading base.